1. Home
  2. WILC vs TRDA Comparison

WILC vs TRDA Comparison

Compare WILC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WILC

G. Willi-Food International Ltd.

HOLD

Current Price

$29.55

Market Cap

347.3M

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$13.94

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WILC
TRDA
Founded
1994
2016
Country
Israel
United States
Employees
N/A
N/A
Industry
Food Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
347.3M
481.6M
IPO Year
2001
2021

Fundamental Metrics

Financial Performance
Metric
WILC
TRDA
Price
$29.55
$13.94
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$21.00
AVG Volume (30 Days)
1.1K
157.9K
Earning Date
05-18-2026
05-07-2026
Dividend Yield
2.98%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$50.80
P/E Ratio
$13.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.22
$4.93
52 Week High
$31.16
$14.49

Technical Indicators

Market Signals
Indicator
WILC
TRDA
Relative Strength Index (RSI) 63.13 58.68
Support Level $25.97 $10.84
Resistance Level $31.02 $13.99
Average True Range (ATR) 0.75 0.73
MACD 0.42 0.03
Stochastic Oscillator 95.25 81.61

Price Performance

Historical Comparison
WILC
TRDA

About WILC G. Willi-Food International Ltd.

G. Willi-Food International Ltd is an Israeli-based company specializing in high-quality, great-tasting kosher food products. The company is engaged, directly and through subsidiaries, in the design, import, marketing and distribution of a variety of over 650 food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Cereals, rice and pastas, and Other Products. The company has one reportable segment: Import- export, marketing and distribution of food products. The majority of the company's revenue is derived from the sale of Dairy and Dairy Substitute Products.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: